Experts discuss integrating BCMA-directed agents in MM treatment, challenges of CAR T-cell availability, potential of bispecific therapies, and ADCs. Emphasis on managing keratopathy, high response rates with combination therapies, and the importance of evaluating BCMA-directed agents in earlier lines of therapy.

Nina Shah and other experts discuss the use of CAR-T therapy in multiple myeloma, highlighting the impressive results of the CRB-401 study and the significance of deep responses. They also explore the improvements in quality of life with IDESL treatment, challenges related to determining treatment lines, and the approval of the first cell-based gene therapy. The podcast covers the safety, efficacy, and ongoing studies of Sulta Cell and the use of T-cell engaging antibodies for multiple myeloma, including factors to consider when selecting therapy.

Guests Gareth Morgan, Nina Shah, and Leif Bergsagel discuss the highlights of Myeloma 2017, including MRD's impact on clinical trials, promising results of nelfinavir and proteasome inhibitor combination therapy, advancements in targeted therapies and imaging, and the consensus on primary principles of MM treatment.